What is AGEN's market cap?

$314.78M, based on the Nov 4 close of $6.97.

What is AGEN's P/E ratio?

3.4× trailing-twelve-month earnings of $91.80M.

Does Agenus pay a dividend?

No regular cash dividend has been paid in the last year.

How much of AGEN is sold short?

7.0M shares, 16.6% of float, as of Oct 15, 2026.

What sector is AGEN in?

Healthcare, in the Biotechnology industry.

NASDAQ · AGENHealthcareBiotechnology

Agenus Inc. (AGEN)

$6.97+4.50%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$6.67▲ 68.01% in range

Nov 3, 2025Low $2.77 · High $9.93Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

Agenus closed at $6.97 on Nov 4, up 4.50%, 29.8% below its 52-week closing high. Volume of 730.9K shares was 0.95× its 20-day average (close to normal).

Split-adjusted performance: -6.9% over one month, +79.2% over six months, +75.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $34.52M, up 34.4% from a year earlier, with a net margin of -1.7%.

Short interest was 7.0M shares at the Oct 15 settlement, up 2.7% from the prior report (16.6% of float, 6.5 days to cover).

Market cap$314.8M45.2M shares

Revenue · quarter$34.5M+34.4% YoY

Diluted EPS$-0.01—

P/E · TTM3.4×P/S 2.4×

Net margin-1.7%Gross 100.0%

Dividend yieldNone

52-week range2.77 – 9.93−29.8% from high

Volume730.9K0.95× 20-day avg

Volatility · 60d88.9%Annualised

Short % of float16.6%6.5 days to cover

Net cash-$11.3MCash $18.7M

Next earnings—Not scheduled

Split-adjusted performance

1W −2.2%1M −6.9%3M −6.9%6M +79.2%YTD +122.0%1Y +75.6%3Y −56.1%5Y −90.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum93

Revenue growth72

Net margin73

Value (low P/E)85

Size54

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →

Shares short7.0M+2.7% vs prior

Days to cover6.5Settled Oct 15

% of float16.6%

Short vol. 10d56.4%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
AGENAgenus	$6.97	+4.50%	+79.2%	+34.4%	−1.7%	3.4	$314.8M
SCTXScribe Therapeutics	$16.78	+3.58%	—	—	—	—	$317.7M	Compare
KYTXKyverna Therapeutics	$5.16	0.00%	−45.5%	—	—	—	$319.1M	Compare
XFORX4 Pharmaceuticals	$3.24	+2.21%	−26.0%	+346.3%	−183.5%	—	$321.2M	Compare
IPSCCentury Therapeutics	$1.67	+9.87%	−28.6%	—	—	—	$302.4M	Compare
OCGNOcugen	$0.8745	+17.35%	−39.9%	+8.4%	−1671.8%	—	$296.6M	Compare
SABSSAB Biotherapeutics	$3.18	+1.92%	−16.3%	—	—	—	$289.3M	Compare
EIKNEikon Therapeutics	$6.39	+15.14%	−35.9%	—	—	—	$346.1M	Compare
FENCFennec Pharmaceuticals	$10.35	−3.27%	+44.2%	+85.2%	11.0%	—	$362.9M	Compare

News about Agenus

All news →

No recent articles focused on Agenus. 1 articles mention it in passing.

Quick answers

What does Agenus do?: Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy.
What is AGEN's market cap?: $314.78M, based on the Nov 4 close of $6.97.
What is AGEN's P/E ratio?: 3.4× trailing-twelve-month earnings of $91.80M.
Does Agenus pay a dividend?: No regular cash dividend has been paid in the last year.
How much of AGEN is sold short?: 7.0M shares, 16.6% of float, as of Oct 15, 2026.
What sector is AGEN in?: Healthcare, in the Biotechnology industry.

About Agenus

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

HQ: Lexington, MA81 employeesListed Feb 4, 2000agenusbio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology